Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on September 23, 2021.
October 12, 2021 at 05:16 am EDT
Share
From September 22, 2021 to September 30, 2021, the company has repurchased 5,252,360 shares, representing 0.65% for CNY 290.42 million. With this, the company has completed the repurchase of 5,252,360 shares, representing 0.65% for CNY 290.42 million under the buyback announced on September 23, 2021.
Jafron Biomedical Co.,Ltd. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Companyâs products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Companyâs products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Companyâs products are applied in 31 provinces, more than 3000 hospitals in China.
JAFRON BIOMEDICAL CO.,LTD. 
